Oral and IV Baclofen in Adult Volunteers

Completed · Phase 1

Conditions studied: Baclofen Withdrawal Syndrome

In brief

The primary objective of this study is to characterize baclofen pharmacokinetics following oral and intravenous administration in patients who are on chronic oral baclofen therapy. The secondary objective is to determine the safety profile of an IV baclofen formulation. This study is a randomized crossover study with two treatment arms. All subjects will receive a dose of oral baclofen and a dose of IV baclofen on separate study days. Whether the oral or intravenous form is given on the first study day will be randomized in a 1:1 manner. The pharmacokinetic and tolerability information gained from this study will support the development of further studies to assess the use of IV baclofen to prevent or treat baclofen withdrawal syndrome.

Key facts

Study ID

NCT01749319

Run by

University of Minnesota

People needed

12

Starts

2013-01-01

Expected to finish

2014-01-01

Last updated by the study team

2014-08-05

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subjects will be eligible to participate in the study if all of the following conditions exist:
• Males and females between the ages of 18-65.
• Subjects are capable of giving informed consent.
• Female subjects must be post-menopausal for at least 1 year, or surgically incapable of bearing children, or practicing at least one or more of the following methods of contraception for three months prior to, and during the study: hormonal, intrauterine device (IUD), or barrier method in combination with a spermicide.
• Subject should be medication free, other than study drug, for 48 hours before through 24 hours after study drug administration. If the need for medication is identified during this time period, it will be discussed with and approved by the PI.

You may not qualify if…

• Subjects will be excluded from participation in the study if any of the following conditions exist:
• Women who are pregnant.
• Women who are breast feeding.
• Subject has a history of intolerance to IV administration of medication.
• Subject has a known hypersensitivity to baclofen.
• Subject has a significant history of cardiac, neurologic, psychiatric, oncologic, endocrine, metabolic, renal or hepatic disease
• Subject has taken or used any investigational drug or device in the 30 days prior to screening.
• Subject has taken either prescribed or over the counter medication for 48 hours prior to baclofen administration on either of the study days.
• Subject reveals clinically significant abnormalities on screening laboratory tests.
• Subject is a non-English speaker, such that ability to ascertain neurological status would require an interpreter.

Where it is running

• University of Minnesota — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.